Introduction: Ponatinib (PON), a third-generation tyrosine kinase inhibitor (TKI) with pan-BCR::ABL1 inhibition, is indicated for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+-ALL). A high proportion of patients with CML and Ph+…